Bacteroides fragilis is a species found in the gut microbiota. A high stool DNA result is a measurement of that species target, not proof of a toxin-producing strain, invasive infection or cancer. Interpreting it starts with separating the species name from the properties of individual strains.
On this page
Why strain differences matter
Some B. fragilis strains have toxin-related properties. Research has studied the effects of B. fragilis toxin on human colonic tissue, but that does not make every B. fragilis strain toxin-producing. A species-level quantity cannot be treated as a toxin test. [1]
What GI-MAP measures
GI-MAP places B. fragilis among commensal or keystone bacteria and reports targeted DNA relative to its laboratory range. This is not a culture of a normally sterile site and does not establish an invasive B. fragilis infection. A high result is a report flag, not proof that the organism has crossed the intestinal wall. [2]
Interpreting a high or low value
Start by confirming that the value belongs to B. fragilis rather than the broader Bacteroidetes phylum. Then consider symptoms, recent antibiotics, stool consistency and why testing was ordered. A low count does not demonstrate an immune deficiency; a high count does not identify an enterotoxin-producing strain.
Research about microbiome composition has not supplied a universal, clinically validated “ideal” abundance for each person. Clinical usefulness of many composition-based interpretations remains uncertain. Avoid using the flag alone to choose a probiotic, antimicrobial or restrictive diet. [3]
B. fragilis, its toxin gene and cancer research
Enterotoxigenic B. fragilis, often shortened to ETBF, refers to strains carrying the B. fragilis toxin gene, bft. That is a more specific finding than a species-level stool quantity. The ordinary B. fragilis line on GI-MAP should not be read as a positive bft result or as direct measurement of toxin activity.
Human research has investigated toxin-gene detection in colonic tissue and its association with colorectal neoplasia. Those studies ask a different question from “how much B. fragilis DNA is in this stool sample?” An association in a research population does not turn a species count into an individual cancer-risk score. [4]
If you encounter a claim that “B. fragilis causes cancer,” check which strain, specimen and outcome the study actually assessed. A genus or species name alone omits those distinctions. Continue ordinary clinician-recommended colorectal screening and investigate concerning symptoms; this marker cannot replace either.
A useful high-or-low result review
- Check the target. B. fragilis is a species; Bacteroidetes is a much broader phylum.
- Read the method and range. A result from a DNA panel is not directly comparable with a percentage from a sequencing test or a culture from another body site.
- Define the concern. Persistent diarrhea, a screening question and an isolated stool flag are different reasons for seeking care.
- Ask what action is supported. A low count does not establish a probiotic deficiency, and a high count does not establish a need to eliminate the organism.
Some gut bacteria contribute to beta-glucuronidase activity, but the two report lines are still different measurements. A species quantity cannot tell you how much of the total enzyme activity came from that organism.
Common questions
Is Bacteroides fragilis always harmful?
No. Its behavior depends on strain and context. A finding in stool is different from an organism causing disease in blood or tissue.
Does a normal count rule out intestinal inflammation?
No. A bacterial quantity is not a direct inflammation assessment. See calprotectin for a different type of stool marker, with its own limitations.
Does a high B. fragilis result mean I have ETBF?
No. A species quantity is not the same as detecting the bft toxin gene. Even a toxin-gene finding needs interpretation in its clinical context.
Does a low result mean I should take a B. fragilis probiotic?
The stool flag does not establish a need for a particular strain or product. Evidence about one strain cannot be assumed to apply to every product with a similar species label.
Sources and review
Sources checked November 1, 2026. Manufacturer material describes the test; clinical guidance and research support the interpretation limits.
- Bacteroides fragilis toxin 2: human-colonic-tissue study, 1999
- Diagnostic Solutions Laboratory: GI-MAP interpretive guide (manufacturer specifications)
- International consensus statement on microbiome testing in clinical practice (2025)
- Purcell et al., 2017: Toxin-gene detection and colorectal neoplasia in human tissue
This article, including the November 1 update, has been reviewed by Madison Ordway, FDN-P. For a correction or source question, contact Gi Map Test.